SynCardia Artificial Heart Safety Should Be Confirmed Postmarket – Panel
This article was originally published in The Gray Sheet
Executive Summary
A postmarket study of SynCardia's CardioWest Total Artificial Heart (TAH) is needed to confirm that its safety remains in the same range as shown in the firm's non-randomized PMA study, according to FDA's Circulatory System Devices Panel
You may also be interested in...
Peer-Reviewed Study Placement Bodes Well For Artificial Heart Approval
SynCardia's artificial heart study is a clinical "triumph" despite its lack of randomization and the relatively few patients who will need the implant, University of Utah cardiologist Dale Runland, MD, opines in a New England Journal of Medicine editorial
Peer-Reviewed Study Placement Bodes Well For Artificial Heart Approval
SynCardia's artificial heart study is a clinical "triumph" despite its lack of randomization and the relatively few patients who will need the implant, University of Utah cardiologist Dale Runland, MD, opines in a New England Journal of Medicine editorial
CardioGenesis Prepares For New Trial Of Percutaneous Laser Angina Device
CardioGenesis credits the recent regulatory progress of its Axcis laser percutaneous myocardial channeling (PMC) system to the contributions of Syncardia CEO Marvin Slepian, MD